AnaptysBio, Inc

(NASDAQ:ANAB)

Latest On AnaptysBio, Inc (ANAB):

Date/Time Type Description Signal Details
2023-05-22 18:46 ESTNewsAnaptysBio upgraded to neutral at JP Morgan on clinical executionN/A
2023-05-21 00:00 ESTNewsStocks To Watch: Debt Ceiling Drama, Nvidia Earnings And Healthcare ConferencesN/A
2023-05-18 17:01 ESTNewsAnaptysBio initiated Outperform at TD Cowen on anti-inflammatory agentsN/A
2023-05-12 06:14 ESTNewsAnaptysBio GAAP EPS of -$1.58 misses by $0.53, revenue of $1.4M misses by $1.48MN/A
2023-04-25 14:45 ESTNewsGSK's Jemperli gets review in EU for expanded use in uterus cancerN/A
2023-03-31 01:05 ESTNewsAnaptysBio: Upside Could Be Lying Ahead Very NicelyN/A
2023-03-01 22:46 ESTNewsAnaptysBio GAAP EPS of -$0.93, revenue of $6.8MN/A
2023-01-13 19:42 ESTNewsAnaptysBio rises 10% on stock repurchase of up to $50MN/A
2022-11-09 02:12 ESTNewsAnaptysBio GAAP EPS of -$1.18 misses by $0.56, revenue of $1.29M misses by $12.14MN/A
2022-11-01 22:23 ESTNewsAnaptysBio raised to Buy at Guggenheim on prospects for checkpoint agonistsN/A
2022-10-05 18:17 ESTNewsAnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trialN/A
2022-09-14 00:51 ESTNewsAnaptysBio cut to Hold at Truist citing high bar for hair loss treatmentN/A
2022-09-12 13:42 ESTNewsAnaptysBio sells royalties from GSK-partnered Zejula for $45MN/A
2022-09-01 01:51 ESTNewsAnaptysBio skin condition candidate fails mid-stage trial; shares down 16%N/A
2022-08-08 18:55 ESTNewsAnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4MN/A
2022-05-04 22:42 ESTNewsAnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08MN/A
2022-03-22 16:43 ESTNewsAnaptysBio names interim CEO as Hamza Suria steps downN/A
2022-03-22 16:42 ESTNewsAnaptysBio cut to neutral at Guggenheim on future of pipelineN/A
2022-03-14 23:38 ESTNewsAnaptysBio acne treatment imsidolimab fails in mid-stage trial; shares down 12%N/A
2021-11-05 01:02 ESTNewsAnaptysBio EPS beats by $0.64, beats on revenueN/A
2021-10-26 12:05 ESTNewsAnaptysBio climbs 14%, will monetize portion of JEMPERLI royalties for $250M with SagardN/A
2021-10-04 23:16 ESTNewsAnaptysBio reports updated data from imsidolimab mid-stage study in pustular psoriasisN/A
2021-08-18 04:46 ESTNewsAnaptysBio secures $20M milestone payment from GSK after JEMPERLI FDA approvalN/A
2021-08-18 04:46 ESTNewsANAB, TLRY, PFMT and BMRN among after hours moversN/A
2021-08-09 22:59 ESTNewsAnaptysBio EPS beats by $0.12, beats on revenueN/A
2021-07-20 18:44 ESTNewsAnaptysBio gains after report the company received a takeover offerN/A
2021-05-05 11:31 ESTNewsAnaptysBio EPS beats by $0.03, beats on revenueN/A
2021-04-24 05:15 ESTNewsAnaptysBio trades higher after FDA approval for Jemperli triggers $20M milestone paymentN/A
2021-04-24 05:14 ESTNewsGlaxoSmithKline wins EU approval for Jemperli in endometrial cancerN/A
2021-04-23 07:49 ESTNewsAnaptysBio is trading higher after FDA approval for Jemperli in endometrial cancer (updated)N/A
2021-03-17 12:05 ESTAnalyst RatingThe Analyst Target Price has increased from $26.75 to $28.5.Buy
2021-03-16 19:18 ESTNewsAnaptysBio is set for a catalyst-rich phase after the recent selloff: TruistN/A
2021-03-10 15:05 ESTAnalyst RatingThe Analyst Target Price has decreased from $30.75 to $26.75.Neutral
2021-03-09 03:06 ESTAnalyst RatingThe Analyst Target Price has decreased from $33.25 to $30.75.Neutral
2021-03-08 17:28 ESTNewsAnaptysBio fails in mid-stage study for Imsidolimab in skin diseaseN/A
2021-03-08 17:27 ESTNewsAnaptysBio gets double downgrade at JPM after Imsidolimab trial failureN/A
2021-03-03 02:39 ESTNewsAnaptysBio: Upcoming Catalyst Seems Like Quite The GambleN/A
2021-03-01 15:05 ESTAnalyst RatingThe Analyst Target Price has increased from $29.8 to $33.25.Buy
2021-03-01 15:05 ESTEarnings EstimateAn EPS average of -$2.43 is estimated for the 2022 year.Sell
2021-03-01 15:05 ESTEarnings EstimateAn EPS average of -$0.69 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-26 15:05 ESTFinancialsCompany financials have been released.Neutral
2021-02-25 19:20 ESTNewsAnaptysBio EPS beats by $0.15, beats on revenueN/A
2021-02-12 11:05 ESTAnalyst RatingThe Analyst Target Price has increased from $28 to $29.8.Neutral
2021-02-11 20:59 ESTNewsAnaptysBio rises after double-upgrade from JPM; positive risk/reward profile citedN/A
2021-02-11 20:58 ESTNewsAnaptysBio: Troubled History Of Drug DevelopmentN/A
2020-12-13 03:11 ESTFinancialsCompany financials have been released.Neutral
2020-12-01 10:36 ESTNewsAnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% UpsideN/A
2020-11-18 06:57 ESTNewsAnaptysBio (ANAB) Investor Presentation - SlideshowN/A
2020-11-15 11:10 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 11:07 ESTAnalyst RatingThe Analyst Target Price has increased from $27.5 to $28.Neutral

About AnaptysBio, Inc (ANAB):

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

See Advanced Chart

General

  • Name AnaptysBio, Inc
  • Symbol ANAB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 94
  • Fiscal Year EndDecember
  • IPO Date2017-01-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.anaptysbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 8.07
  • Price/Book (Most Recent Quarter) 1.53
  • Enterprise Value Revenue 2.85
  • Enterprise Value EBITDA 0.11
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.01
  • Next Year EPS Estimate -$3.09
  • Next Quarter EPS Estimate -$0.61
  • Profit Margin -27%
  • Operating Margin -32%
  • Return on Assets -4%
  • Return on Equity -5%
  • Revenue 75 million
  • Earnings Per Share -$3.01
  • Revenue Per Share $2.75
  • Gross Profit -5025000
  • Quarterly Earnings Growth 1900%
View More

Highlights

  • Market Capitalization 587.28 million
  • EBITDA -87543000
  • PE Ratio -6.14
  • Analyst Target Price $28.5
  • Book Value Per Share $14.50
View More

Share Statistics

  • Shares Outstanding 27.37 million
  • Shares Float 15.89 million
  • % Held by Insiders 77%
  • % Held by Institutions 106.22%
  • Shares Short 3.81 million
  • Shares Short Prior Month 3.74 million
  • Short Ratio 8.99
  • Short % of Float 21%
  • Short % of Shares Outstanding 14%
View More

Technicals

  • Beta 0.13
  • 52 Week High $35.86
  • 52 Week Low $12.46
  • 50 Day Moving Average 26.72
  • 200 Day Moving Average 23.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

AnaptysBio, Inc (ANAB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

AnaptysBio, Inc (ANAB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$60 million$1.20$0.6098.87%
2020-09-302020-11-04$N/A-$0.87-$0.69-26.45%
2020-06-302020-08-10$N/A-$0.79-$0.65-21.18%
2020-03-312020-05-06$N/A-$0.30-$0.8062.5%
2019-12-312020-03-02$3 million-$0.75-$1.2841.36%
2019-09-302019-11-08$N/A-$1.15-$1.14-0.46%
2019-06-302019-08-08$5 million-$0.89-$0.956.66%
2019-03-312019-05-07$N/A-$0.82-$0.78-4.75%
2018-12-312019-02-28$N/A-$0.64-$0.8625.93%
2018-09-302018-11-08$5 million-$0.66-$0.706.16%
2018-06-302018-08-07$N/A-$0.57-$0.6714.41%
2018-03-312018-05-08$N/A-$0.63-$0.46-36.22%
2017-12-312018-03-05$3 million-$0.30-$0.4228.37%
2017-09-302017-11-07$-7000000-$0.45-$0.474.56%
2017-06-302017-08-10$7 million-$0.13-$0.4269.34%
2017-03-312017-05-11$N/A-$0.75-$0.18-310.96%
2016-12-312017-03-08$2.75 million-$0.19-$0.10-86.34%

AnaptysBio, Inc (ANAB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

AnaptysBio, Inc (ANAB) Chart:

AnaptysBio, Inc (ANAB) News:

Below you will find a list of latest news for AnaptysBio, Inc (ANAB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AnaptysBio, Inc (ANAB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-07-18100CALL0 0230.68TRUE00
2025-07-1812.50CALL0 0258.23TRUE00
2025-07-18150CALL0 0199.21TRUE00
2025-07-1817.55.4CALL0 7148.53TRUE00
2025-07-18204.75CALL0 2693.63TRUE00
2025-07-1822.52.21CALL0 100470.81TRUE00
2025-07-18251.28CALL0 2893.91FALSE00
2025-07-18300.05CALL0 34097.82FALSE00
2025-07-18350CALL0 0131.84FALSE00
2025-07-18100PUT0 0501.32FALSE00
2025-07-1812.50.55PUT0 20397.49FALSE00
2025-07-18150.05PUT0 0150.23FALSE00
2025-07-1817.50.15PUT1 101684.44FALSE0.150
2025-07-18200.44PUT1 11675.84FALSE0.440
2025-07-1822.50.9PUT30 3558.6FALSE0.90
2025-07-18252.97PUT0 367.56TRUE00
2025-07-18300PUT0 0100.48TRUE00
2025-07-18350PUT0 0133.48TRUE00
2025-08-152.50CALL0 0295.93TRUE00
2025-08-1550CALL0 0238.37TRUE00
2025-08-157.50CALL0 0174.63TRUE00
2025-08-151013CALL0 112204.54TRUE00
2025-08-1512.50CALL0 2172.7TRUE00
2025-08-15159.41CALL0 24132.98TRUE00
2025-08-1517.55.8CALL0 221110.43TRUE00
2025-08-15204.2CALL0 6368.25TRUE00
2025-08-1522.53.3CALL0 1367.84TRUE00
2025-08-15251.7CALL0 16163.69FALSE00
2025-08-15300.95CALL0 6074.52FALSE00
2025-08-15350.4CALL0 9145.09FALSE00
2025-08-152.50PUT0 01492.47FALSE00
2025-08-1550PUT0 0598.71FALSE00
2025-08-157.50PUT0 5430.77FALSE00
2025-08-15100.4PUT0 25333.43FALSE00
2025-08-1512.50PUT0 7264.51FALSE00
2025-08-15151.1PUT0 21136.58FALSE00
2025-08-1517.52.35PUT0 17106.06FALSE00
2025-08-15200PUT0 18111.2FALSE00
2025-08-1522.51.95PUT0 1767.13FALSE00
2025-08-15254.5PUT0 1371.96TRUE00
2025-08-15300PUT0 175.02TRUE00
2025-08-15350PUT0 0115.19TRUE00
2025-11-212.50CALL0 0181.98TRUE00
2025-11-2150CALL0 0154.48TRUE00
2025-11-217.50CALL0 0163.17TRUE00
2025-11-21100CALL0 0127.05TRUE00
2025-11-2112.50CALL0 1107.79TRUE00
2025-11-21150CALL0 099.51TRUE00
2025-11-2117.50CALL0 19877.02TRUE00
2025-11-21205.48CALL0 6671.21TRUE00
2025-11-2122.50CALL0 1674.83TRUE00
2025-11-21254.62CALL0 971.05FALSE00
2025-11-21302.9CALL0 23668.83FALSE00
2025-11-21350CALL0 187.27FALSE00
2025-11-212.50PUT0 00FALSE00
2025-11-2150PUT0 0350.9FALSE00
2025-11-217.50PUT0 0252.6FALSE00
2025-11-21100PUT0 0195.77FALSE00
2025-11-2112.50PUT0 5112.29FALSE00
2025-11-21150.85PUT0 487.89FALSE00
2025-11-2117.50PUT0 076.46FALSE00
2025-11-21200PUT0 279.53FALSE00
2025-11-2122.54PUT0 176.07FALSE00
2025-11-21250PUT0 063.79TRUE00
2025-11-21300PUT0 076.06TRUE00
2025-11-21350PUT0 074.03TRUE00
2026-01-1612.50CALL0 091.65TRUE00
2026-01-16150CALL0 090.68TRUE00
2026-01-1617.56CALL0 177.62TRUE00
2026-01-16207CALL0 1072.44TRUE00
2026-01-1622.50CALL0 070.48TRUE00
2026-01-16254CALL0 971.69FALSE00
2026-01-16300CALL0 069.07FALSE00
2026-01-16350CALL0 071.42FALSE00
2026-01-1612.50PUT0 0106.25FALSE00
2026-01-16150PUT0 094.79FALSE00
2026-01-1617.51.9PUT0 378.62FALSE00
2026-01-16204PUT0 575.41FALSE00
2026-01-1622.50PUT0 069.19FALSE00
2026-01-16250PUT0 073.2TRUE00
2026-01-16300PUT0 070.68TRUE00
2026-01-163512.4PUT0 1072.56TRUE00
2026-02-2012.50CALL0 096.78TRUE00
2026-02-20150CALL0 082.9TRUE00
2026-02-2017.50CALL0 078.39TRUE00
2026-02-20200CALL0 075.82TRUE00
2026-02-2022.50CALL0 068.12TRUE00
2026-02-20250CALL0 071.83FALSE00
2026-02-20300CALL0 067.78FALSE00
2026-02-20350CALL0 072.1FALSE00
2026-02-2012.50PUT0 084.08FALSE00
2026-02-20150PUT0 094.59FALSE00
2026-02-2017.50PUT0 075.87FALSE00
2026-02-20200PUT0 063.84FALSE00
2026-02-2022.50PUT0 067.71FALSE00
2026-02-20250PUT0 073.73TRUE00
2026-02-20300PUT0 066.17TRUE00
2026-02-20350PUT0 070.36TRUE00

Latest ANAB Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST8$21.35
Jun 13, 2022 7:59 PM EST1$21.35
Jun 13, 2022 7:59 PM EST200$21.35
Jun 13, 2022 7:59 PM EST54$21.35
Jun 13, 2022 7:59 PM EST13$21.35

AnaptysBio, Inc (ANAB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2018-09-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1370053/000000000018028147/0000000000-18-028147-index.htm
2018-10-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1370053/000000000018032332/0000000000-18-032332-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000009375120000338/0000093751-20-000338-index.htm
2019-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000021545719003201/0000215457-19-003201-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000031506619000857/0000315066-19-000857-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000031506619001800/0000315066-19-001800-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000083423720004777/0000834237-20-004777-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000090266419000927/0000902664-19-000927-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000090266420000965/0000902664-20-000965-index.htm
2020-02-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000092189520000234/0000921895-20-000234-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000092963819000269/0000929638-19-000269-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093247119004736/0000932471-19-004736-index.htm
2019-11-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093583619000611/0000935836-19-000611-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000093583620000141/0000935836-20-000141-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000436/0001012975-18-000436-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000437/0001012975-18-000437-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000101297518000438/0001012975-18-000438-index.htm
2018-05-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1370053/000107261318000346/0001072613-18-000346-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000110465920018330/0001104659-20-018330-index.htm
2018-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518089132/0001193125-18-089132-index.htm
2018-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518095907/0001193125-18-095907-index.htm
2018-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518280420/0001193125-18-280420-index.htm
2018-09-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1370053/000119312518281156/0001193125-18-281156-index.htm
2018-09-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1370053/000119312518283918/0001193125-18-283918-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312518283933/0001193125-18-283933-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1370053/000119312519041203/0001193125-19-041203-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000119312520225721/0001193125-20-225721-index.htm
2018-03-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118017376/0001209191-18-017376-index.htm
2018-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118017377/0001209191-18-017377-index.htm
2018-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-07-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-08-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118045891/0001209191-18-045891-index.htm
2018-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118045892/0001209191-18-045892-index.htm
2018-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009006/0001209191-19-009006-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009024/0001209191-19-009024-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009028/0001209191-19-009028-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009031/0001209191-19-009031-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009034/0001209191-19-009034-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009036/0001209191-19-009036-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009038/0001209191-19-009038-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009043/0001209191-19-009043-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009044/0001209191-19-009044-index.htm
2019-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119009046/0001209191-19-009046-index.htm
2019-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119046820/0001209191-19-046820-index.htm
2019-09-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119050888/0001209191-19-050888-index.htm
2019-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119050889/0001209191-19-050889-index.htm
2019-11-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2019-12-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119059923/0001209191-19-059923-index.htm
2019-12-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119059924/0001209191-19-059924-index.htm
2019-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919119060981/0001209191-19-060981-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009309/0001209191-20-009309-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009316/0001209191-20-009316-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009322/0001209191-20-009322-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009325/0001209191-20-009325-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009327/0001209191-20-009327-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120009329/0001209191-20-009329-index.htm
2020-03-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2020-07-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042503/0001209191-20-042503-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042505/0001209191-20-042505-index.htm
2020-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120042506/0001209191-20-042506-index.htm
2020-07-313Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120044257/0001209191-20-044257-index.htm
2020-07-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1370053/000120919120044259/0001209191-20-044259-index.htm
2019-11-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000121465919007372/0001214659-19-007372-index.htm
2018-06-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417318000087/0001274173-18-000087-index.htm
2019-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417319000033/0001274173-19-000033-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000127417319000125/0001274173-19-000125-index.htm
2019-08-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000131924419000074/0001319244-19-000074-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000131924420000020/0001319244-20-000020-index.htm
2018-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000020/0001370053-18-000020-index.htm
2018-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000022/0001370053-18-000022-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000026/0001370053-18-000026-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000027/0001370053-18-000027-index.htm
2018-05-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000029/0001370053-18-000029-index.htm
2018-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000031/0001370053-18-000031-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000036/0001370053-18-000036-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000037/0001370053-18-000037-index.htm
2018-09-1410-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000041/0001370053-18-000041-index.htm
2018-09-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000042/0001370053-18-000042-index.htm
2018-09-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000043/0001370053-18-000043-index.htm
2018-09-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000046/0001370053-18-000046-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005318000051/0001370053-18-000051-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005318000052/0001370053-18-000052-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000004/0001370053-19-000004-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000006/0001370053-19-000006-index.htm
2019-02-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000007/0001370053-19-000007-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000013/0001370053-19-000013-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000014/0001370053-19-000014-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000018/0001370053-19-000018-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000019/0001370053-19-000019-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000021/0001370053-19-000021-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000026/0001370053-19-000026-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000027/0001370053-19-000027-index.htm
2019-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000029/0001370053-19-000029-index.htm
2019-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000031/0001370053-19-000031-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000035/0001370053-19-000035-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005319000041/0001370053-19-000041-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005319000042/0001370053-19-000042-index.htm
2020-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000003/0001370053-20-000003-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000007/0001370053-20-000007-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000009/0001370053-20-000009-index.htm
2020-03-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000010/0001370053-20-000010-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000013/0001370053-20-000013-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000019/0001370053-20-000019-index.htm
2020-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000020/0001370053-20-000020-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000025/0001370053-20-000025-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000026/0001370053-20-000026-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000042/0001370053-20-000042-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000045/0001370053-20-000045-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000050/0001370053-20-000050-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000051/0001370053-20-000051-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000053/0001370053-20-000053-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000057/0001370053-20-000057-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1370053/000137005320000064/0001370053-20-000064-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1370053/000137005320000065/0001370053-20-000065-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000162363220000230/0001623632-20-000230-index.htm
2020-04-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1370053/000162363220000855/0001623632-20-000855-index.htm

AnaptysBio, Inc (ANAB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AnaptysBio, Inc (ANAB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 77%
Institutional Ownership: 10622%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-03Dominic PiscitelliChief Financial OfficerSell1,100.0075.8183,390.010.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell4,820.0072.24348,212.2210,022.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell6,624.0074.33492,361.921,100.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-09-07Marco LondeiChief Medical OfficerBuy142,857.000.7099,999.90144,877.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell6,741.0068.47461,577.84144,877.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell18,604.0071.331,327,060.5314,842.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell8,002.0067.57540,683.94151,618.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerBuy8,048.000.705,633.60152,925.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell3,185.0066.38211,416.16159,620.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerSell12,120.0065.36792,177.74162,805.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17Marco LondeiChief Medical OfficerBuy22,000.006.93152,460.00174,925.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-06-10Hamza SuriaPresident, CEOSell454.0076.3134,644.7417,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10Hamza SuriaPresident, CEOSell1,994.0075.86151,270.8218,090.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10Hamza SuriaPresident, CEOSell5,000.0074.68373,412.5020,084.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-01-15Marco LondeiChief Medical OfficerSell14,894.0070.041,043,195.1222,377.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell2,003.0074.50149,219.0922,377.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell2,048.0073.43150,383.8224,380.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-10Hamza SuriaPresident, CEOSell6,440.0073.70474,637.0225,084.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04Marco LondeiChief Medical OfficerSell6,009.0072.45435,358.6626,428.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-04-16Nicholas LydonDirectorSell2,222.0090.26200,549.05271,106.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16Nicholas LydonDirectorSell2,803.0089.42250,631.37273,328.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-08Hamza SuriaPresident, CEOBuy22,428.002.5958,088.5227,426.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-04-16Nicholas LydonDirectorSell4,250.0088.30375,267.35276,131.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-11-22Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0027,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2018-04-16Nicholas LydonDirectorSell9,425.0087.46824,340.66280,381.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-07-09Hamza SuriaPresident, CEOBuy1,428.002.243,198.7228,854.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-04-16Nicholas LydonDirectorSell1,390.0086.15119,752.95289,806.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16Nicholas LydonDirectorSell10,310.0085.11877,491.32291,196.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-12-11Hamza SuriaPresident, CEOSell4,998.0070.83354,008.3430,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12Hamza SuriaPresident, CEOSell8,324.0072.88606,618.1630,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-14Hamza SuriaPresident, CEOSell7,800.0070.51549,978.7830,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2019-01-14Hamza SuriaPresident, CEOSell12,240.0071.10870,304.3930,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-04-16Nicholas LydonDirectorSell2,600.0084.18218,879.96301,506.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-06-10Hamza SuriaPresident, CEOSell8,540.0072.64620,384.8831,524.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04Marco LondeiChief Medical OfficerBuy10,060.000.707,042.0032,437.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell3,554.0070.34249,974.1433,446.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-07-09Hamza SuriaPresident, CEOBuy6,208.001.619,994.8835,062.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-12-10Hamza SuriaPresident, CEOSell4,964.0072.48359,805.1235,062.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-12-10J. Anthony WareDirectorBuy3,600.0014.0550,580.003,600.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerBuy37,000.0011.34419,580.0037,000.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2019-01-15Marco LondeiChief Medical OfficerSell4,181.0069.29289,686.4437,271.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2020-02-05Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0037,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2018-12-14Hamza SuriaPresident, CEOSell9,084.0069.68632,967.6737,864.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-12Hamza SuriaPresident, CEOSell9,673.0071.92695,717.9538,388.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOSell10,347.0071.49739,700.8240,026.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-04-17Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0040,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-01-15Marco LondeiChief Medical OfficerBuy19,075.006.93132,189.7541,452.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-14Hamza SuriaPresident, CEOSell27,760.0070.651,961,227.3442,304.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14Hamza SuriaPresident, CEOSell24,844.0068.891,711,428.6346,948.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2020-03-10Hamza SuriaPresident, CEOBuy10,000.001.1211,200.0047,636.00https://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2018-12-12Hamza SuriaPresident, CEOSell12,003.0071.11853,480.5248,061.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOSell15,276.0070.571,078,082.3150,373.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12Hamza SuriaPresident, CEOBuy30,000.001.1233,600.0060,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10Hamza SuriaPresident, CEOBuy30,587.001.1234,257.4465,649.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-11-27Marco LondeiChief Medical OfficerBuy46,202.006.93320,179.8668,579.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-01-14Hamza SuriaPresident, CEOBuy40,000.001.1244,800.0070,064.00https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14Hamza SuriaPresident, CEOBuy41,728.001.1246,735.3671,792.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-03Dominic PiscitelliChief Financial OfficerSell2,298.0073.18168,158.687,724.00https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm